title: Prevalence and predictive factors of anemia after renal transplantation: a Moroccan report.
abstract: OBJECTIVE
  Anemia, a common multifactorial problem in kidney transplant recipients, represents an important cardiovascular risk factor. The purpose of this study was to assess anemia prevalence after kidney transplantation, the main factors involved in its occurrence, its cardiovascular consequences, and its impact on patient survival and graft function.
  
  
  METHODS
  This retrospective study evaluated 69 patients undergoing renal transplantation between January 1998 and September 2008 with ≥1 year of follow-up. For all of the patients, we recorded hemoglobin concentrations before and at 1, 3, 6, 12, 36, and 60 months after transplantation. Anemia was defined as recommended by the American Society of Transplantation: hemoglobin level <12 g/dL in women and <13 g/dL in men. To determine the factors involved in anemia occurrence, we compared 2 groups of patients, with versus without anemia, at various times after renal transplantation.
  
  
  RESULTS
  This study showed a high prevalence of anemia in the early posttransplantation period of 82.7% and 42% of kidney transplantation patients at 1 month and 6 months, respectively. It was mainly related to a low pretransplant hemoglobin level. The prevalence declined to 37.7% at 1 year. Renal graft dysfunction was the most important factor in the occurrence of late post-renal transplantation anemia. The presence of anemia increased the risk of renal graft functional deterioration by a factor of 2.9. The decreased prevalence at 1 year after transplantation was significantly associated with a reduction in left ventricular hypertrophy.
  
  
  CONCLUSIONS
  The management of anemia is essential to improve renal graft survival, reduce cardiovascular morbidity, and ensure a better quality of life for renal transplant recipients.
authors.affiliation: Department of Nephrology, Unit of Nephrology-Dialysis-Renal Transplantation, Université Mohammed V, Faculté de Médecine et de pharmacie de Rabat, Morocco. aicha_radoui@hotmail.com
authors.forename: A
authors.initials: A
authors.lastname: Radoui
authors.forename: Z
authors.initials: Z
authors.lastname: Skalli
authors.forename: I
authors.initials: I
authors.lastname: Haddiya
authors.forename: L
authors.initials: L
authors.lastname: Benamar
authors.forename: F
authors.initials: F
authors.lastname: Ezzaitouni
authors.forename: N
authors.initials: N
authors.lastname: Ouzeddoun
authors.forename: R
authors.initials: R
authors.lastname: Bayahia
authors.forename: H
authors.initials: H
authors.lastname: Rhou
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000740:Anemia / Q000097:blood / Q000188:drug therapy / Q000453:epidemiology* / Q000209:etiology* / Q000401:mortality; D015415:Biomarkers / Q000097:blood; D002318:Cardiovascular Diseases / Q000453:epidemiology; D004921:Erythropoietin / Q000627:therapeutic use; D005260:Female; D006085:Graft Survival; D006397:Hematinics / Q000627:therapeutic use; D006454:Hemoglobins / Q000378:metabolism; D006801:Humans; D016030:Kidney Transplantation / Q000009:adverse effects* / Q000401:mortality; D008297:Male; D008875:Middle Aged; D009018:Morocco / Q000453:epidemiology; D015995:Prevalence; D011994:Recombinant Proteins; D012189:Retrospective Studies; D018570:Risk Assessment; D012307:Risk Factors; D012720:Severity of Illness Index; D013997:Time Factors; D055815:Young Adult
chemical_list: D015415:Biomarkers; D006397:Hematinics; D006454:Hemoglobins; D011994:Recombinant Proteins; D004921:Erythropoietin